Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the Alopecia Areata Symptom Impact Scale (AASIS) is a better tool than the Alopecia Areata Quality of Life Index (AA-QLI) for assessing patient-reported outcomes in alopecia areata.

In this study, patient-reported outcomes indicated that greater weight loss with GLP-1RA treatments was associated with increased reports of adverse cosmetic effects such as skin laxity, facial volume loss, and hair shedding, despite improvements in some preexisting inflammatory skin conditions.

This protocol outlines a study aiming to develop a universal patient-reported outcome measure for various hair disorders through qualitative interviews, with no new clinical results reported yet.

The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.

In this study, data from multiple sources found that Baricitinib significantly promoted hair regrowth and improved patient-reported outcomes in those with severe alopecia, with minimal side effects, over a 36-week period.

In this case report, a 45-year-old woman with systemic lupus erythematosus underwent a six-month integrative naturopathic and yoga program while continuing conventional treatment, aiming to document improvements in disease management and patient well-being.

This study found that the Alopecia Areata Patient Priority Outcomes questionnaire is a reliable and valid tool for measuring the severity and impact of hair loss in individuals with alopecia areata.

This study developed the Alopecia Areata Patient Priority Outcome (AAPPO), a new tool designed to measure and capture the symptoms and impacts of alopecia areata that matter most to patients.

In this study, 80% of patients expressed satisfaction with diode-laser hair removal, though multiple treatments were needed for optimal results and were a deterrent for some.

This study suggests that sustained hair regrowth is necessary to significantly change patient-reported psychosocial outcomes in alopecia areata, with time since regrowth being a critical factor in measuring adaptation.

JAK inhibitors help regrow eyebrow and eyelash hair and improve anxiety and depression in some alopecia areata patients.

In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.

The authors concluded that for alopecia areata, addressing psychosocial well-being and social functioning is crucial, as the burden of the condition extends beyond visible hair loss and includes substantial inequities in treatment access.

In this prospective cohort, baseline severity, disease activity, and relapse history were identified as key factors influencing response and recurrence in alopecia areata, suggesting that implementing standardized assessments could enhance risk stratification and personalized care approaches.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

This review identified various outcome measure instruments for assessing androgenetic alopecia but found inconsistent application across clinical trials, underscoring the need for standardized assessment methods.

This study developed two comprehensive patient-reported outcome measures for systemic lupus erythematosus to assess symptom fluctuations and impacts, following FDA guidelines, which may aid in clinical studies and practice.

This qualitative study reported that platelet-rich plasma treatments improved patient satisfaction and quality of life by enhancing facial texture and hair quality, supporting PRP as a viable option for conditions like alopecia and skin rejuvenation.

In this study, most patients who underwent endoscopic brow-lift reported being satisfied with the procedure, noting improvements in appearance and confidence, with minimal and short-lived side effects.

The study on androgenetic alopecia reported that microneedling with concentrated growth factor significantly improved hair regrowth in patients over two years, without age influencing the outcome, and recorded no significant adverse reactions.

This study reported that in embryo transfer cycles for women with nonclassic 21-hydroxylase deficiency, dexamethasone use was associated with improved pregnancy rates, and maintaining a BMI below 23.36 kg/m² increased pregnancy probabilities.

This study found that androgenic alopecia patients using Propecia reported a significant decrease in Quality of Life compared to those using Minoxidil, particularly in the area of emotional role limitations.

This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.

In this study of 454 ICU survivors of severe COVID-19 one year after discharge, 10.2% mortality was observed, and substantial declines in health-related quality of life and increased frailty were reported, implying a need for comprehensive post-ICU care.

This study concluded that while CDK4/6 inhibitors, used to treat HR+ HER2- metastatic breast cancer, generally did not worsen health-related quality of life, they were associated with increased patient-reported issues like diarrhea and hair loss upset.

This study found that the Cutaneous Lupus Disease Area and Severity Index (CLASI) is correlated with both physician-assessed and patient-reported outcomes in cutaneous lupus erythematosus, particularly highlighting concerns about body image in visible areas.

This study examined the clinicopathological characteristics of cutaneous squamous cell carcinoma on the scalp and ear but reported no new results on its association with androgenetic alopecia.

This study reviewed evidence on injectable regenerative treatments for female pattern hair loss, finding that while PRP consistently improves hair density and thickness, the impact of such treatments on psychological wellbeing remains unclear, and patient-reported outcomes are inconsistently assessed.

This study found that autologous platelet-rich plasma significantly improved hair follicle number, thickness, and density in patients with androgenic alopecia compared to placebo, with high reported patient satisfaction.